Best treatments for multiple myeloma

Understanding multiple myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell found in the bone marrow that normally makes antibodies to help fight infection. In myeloma, abnormal plasma cells (myeloma cells) build up in the bone marrow and can form tumors in the bones. These cells make an abnormal antibody protein (called M protein) and can crowd out healthy blood cells, leading to low blood counts. Presentation varies: some people have no symptoms at first (smoldering myeloma), while others have bone pain (often in the back or ribs), bones that break easily, weakness and fatigue, frequent infections, kidney problems, or high blood calcium causing thirst, constipation, or confusion. Diagnosis typically combines blood and urine tests (including immunoglobulin studies), a bone marrow biopsy, and imaging. Stage is based on factors including blood beta-2-microglobulin and albumin levels, along with other markers. Care is coordinated by a specialist team and may involve active treatment or, for early disease without symptoms, careful monitoring. This is general information, not medical advice.

Frequently asked

What treats multiple myeloma?

Our catalog lists 26 products that may treat multiple myeloma, based on NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. They're rated where FDA recall-safety data exists; the current top-rated option is empliciti.

What is the best-rated treatment for multiple myeloma?

By our independent recall-safety rating — not an efficacy measure — empliciti ranks highest among the products we list for multiple myeloma. Always consult a professional.

How are these treatments ranked?

By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.

What types of drugs treat multiple myeloma?

Treatments for multiple myeloma span FDA drug classes including thalidomide analog, hematopoietic stem cell mobilizer, bisphosphonate, alkylating drug, proteasome inhibitor. Compare every option side by side, ranked by independent rating, above.

Treatment associations are derived from NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. This is general reference, not medical advice — always consult a licensed professional.